source
- Novartis shares tumble as three late-stage drug candidates fail trialsNovartis' stock fell more than 13% this week after news that three of its late-stage programs did not meet expectations, pulling down other pharma stocks in the market. The antibody‑oligonucleotid…
- FDA leadership stabilizes under new CBER and CDER heads and appoints first AI deputy commissionerAt the Food and Drug Administration, Karim Mikhail and Michael Davis have been confirmed as the permanent heads of the Center for Biologics Evaluation and Research and the Center for Drug Evaluatio…